Capricor stock plunges after FDA rejects Duchenne drug application

Published 11/07/2025, 12:00
© Reuters.

Investing.com -- Capricor Therapeutics (NASDAQ:CAPR) stock plunged 53% after the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) rejecting its application for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD).

The FDA stated that the Biologics License Application (BLA) "does not meet the statutory requirement for substantial evidence of effectiveness" and requires additional clinical data. The agency also noted outstanding Chemistry, Manufacturing, and Controls (CMC) issues, though Capricor believes it had addressed most of these in prior communications.

Capricor CEO Linda Marbán expressed surprise at the decision, noting that "prior to the CRL, the review had advanced without major issues, including a successful pre-licensure inspection and completion of the mid-cycle review." The company had been granted Priority Review for the application in March 2025.

The biotechnology company now plans to resubmit its BLA with data from its ongoing Phase 3 HOPE-3 trial, which is expected to produce topline results in Q3 2025. The HOPE-3 study is a randomized, double-blind, placebo-controlled trial involving 104 patients.

The FDA has offered Capricor the opportunity to request a Type A meeting to discuss next steps toward potential approval. The company remains focused on pursuing the indication for treating cardiomyopathy associated with DMD.

Capricor’s original submission included data from the HOPE-2 trial, its open-label extension, and natural history comparisons from FDA-funded datasets, which ultimately proved insufficient for approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.